FR2829768B1 - Utilisation de peptides comportant des modifications de type post-traductionnel dans le cadre du traitement de pathologies auto-immunes - Google Patents

Utilisation de peptides comportant des modifications de type post-traductionnel dans le cadre du traitement de pathologies auto-immunes

Info

Publication number
FR2829768B1
FR2829768B1 FR0112041A FR0112041A FR2829768B1 FR 2829768 B1 FR2829768 B1 FR 2829768B1 FR 0112041 A FR0112041 A FR 0112041A FR 0112041 A FR0112041 A FR 0112041A FR 2829768 B1 FR2829768 B1 FR 2829768B1
Authority
FR
France
Prior art keywords
peptides
tyr
amino acid
post
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
FR0112041A
Other languages
English (en)
French (fr)
Other versions
FR2829768A1 (fr
Inventor
Sylviane Muller
Fanny Sylvie Michele Monneaux
Jean Paul Briand
Gilles Guichard
Jean Gerard Guillet
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Original Assignee
Centre National de la Recherche Scientifique CNRS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR0112041A priority Critical patent/FR2829768B1/fr
Application filed by Centre National de la Recherche Scientifique CNRS filed Critical Centre National de la Recherche Scientifique CNRS
Priority to EP10183969A priority patent/EP2338908A1/fr
Priority to JP2003528859A priority patent/JP4160505B2/ja
Priority to EP02798771A priority patent/EP1427755A2/fr
Priority to AU2002362383A priority patent/AU2002362383B2/en
Priority to PCT/FR2002/003186 priority patent/WO2003025014A2/fr
Priority to US10/489,967 priority patent/US7872098B1/en
Priority to CA002460704A priority patent/CA2460704A1/fr
Publication of FR2829768A1 publication Critical patent/FR2829768A1/fr
Application granted granted Critical
Publication of FR2829768B1 publication Critical patent/FR2829768B1/fr
Priority to US12/913,232 priority patent/US8475800B2/en
Priority to US13/914,997 priority patent/US20140004136A1/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Communicable Diseases (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Biotechnology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
FR0112041A 2001-09-18 2001-09-18 Utilisation de peptides comportant des modifications de type post-traductionnel dans le cadre du traitement de pathologies auto-immunes Expired - Lifetime FR2829768B1 (fr)

Priority Applications (10)

Application Number Priority Date Filing Date Title
FR0112041A FR2829768B1 (fr) 2001-09-18 2001-09-18 Utilisation de peptides comportant des modifications de type post-traductionnel dans le cadre du traitement de pathologies auto-immunes
CA002460704A CA2460704A1 (fr) 2001-09-18 2002-09-18 Utilisation de peptides comportant des modifications de type post-traductionnel dans le cadre du traitement de pathologies auto-immunes
EP02798771A EP1427755A2 (fr) 2001-09-18 2002-09-18 Utilisation de peptides comportant des modifications de type post-traductionnel dans le cadre du traitement de pathologies auto-immunes
AU2002362383A AU2002362383B2 (en) 2001-09-18 2002-09-18 Use of peptides comprising post-translational modifications in the treatment of autoimmune pathologies
PCT/FR2002/003186 WO2003025014A2 (fr) 2001-09-18 2002-09-18 Utilisation de peptides comportant des modifications de type post-traductionnel dans le cadre du traitement de pathologies auto-immunes
US10/489,967 US7872098B1 (en) 2001-09-18 2002-09-18 Phosphorylated derivatives of a U1-70K peptide and their use in the treatment of autoimmune pathologies
EP10183969A EP2338908A1 (fr) 2001-09-18 2002-09-18 Peptides comportant des modifications de type post-translationnel et leur utilisation dans le cadre du traitement de pathologies auto-immunes
JP2003528859A JP4160505B2 (ja) 2001-09-18 2002-09-18 自己免疫疾患の治療の構想における翻訳後型修飾を含むペプチドの使用
US12/913,232 US8475800B2 (en) 2001-09-18 2010-10-27 Phosphorylated derivatives of a U1-70K peptide and their use in the treatment of autoimmune pathologies
US13/914,997 US20140004136A1 (en) 2001-09-18 2013-06-11 Phosphorylated derivatives of a u1-70k peptide and their use in the treatment of autoimmune pathologies

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0112041A FR2829768B1 (fr) 2001-09-18 2001-09-18 Utilisation de peptides comportant des modifications de type post-traductionnel dans le cadre du traitement de pathologies auto-immunes

Publications (2)

Publication Number Publication Date
FR2829768A1 FR2829768A1 (fr) 2003-03-21
FR2829768B1 true FR2829768B1 (fr) 2003-12-12

Family

ID=8867384

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0112041A Expired - Lifetime FR2829768B1 (fr) 2001-09-18 2001-09-18 Utilisation de peptides comportant des modifications de type post-traductionnel dans le cadre du traitement de pathologies auto-immunes

Country Status (7)

Country Link
US (3) US7872098B1 (enExample)
EP (2) EP2338908A1 (enExample)
JP (1) JP4160505B2 (enExample)
AU (1) AU2002362383B2 (enExample)
CA (1) CA2460704A1 (enExample)
FR (1) FR2829768B1 (enExample)
WO (1) WO2003025014A2 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030186849A1 (en) * 2001-09-06 2003-10-02 Zimmer Robert H. Modified peptides and their use for the treatment of autoimmune diseases
FR2931360B1 (fr) * 2008-05-20 2012-05-18 Centre Nat Rech Scient Nanoparticules contenant un peptide, vecteurs les contenant et utilisations pharmaceutiques desdits nanoparticules et vecteurs
IN2014MN01376A (enExample) 2011-12-13 2015-04-17 Centre Nat Rech Scient
US10213482B2 (en) 2014-12-12 2019-02-26 Immupharma France Sa Methods of treating chronic inflammatory diseases
US20210308211A1 (en) * 2020-03-29 2021-10-07 Immupharma France Sa Method of treating viral infections
CN119241701A (zh) * 2024-09-27 2025-01-03 珠海丽禾医疗诊断产品有限公司 U1-70k结合蛋白、制备方法和应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030186849A1 (en) * 2001-09-06 2003-10-02 Zimmer Robert H. Modified peptides and their use for the treatment of autoimmune diseases

Also Published As

Publication number Publication date
US8475800B2 (en) 2013-07-02
EP2338908A1 (fr) 2011-06-29
JP4160505B2 (ja) 2008-10-01
US20120149652A1 (en) 2012-06-14
FR2829768A1 (fr) 2003-03-21
JP2005510469A (ja) 2005-04-21
US7872098B1 (en) 2011-01-18
WO2003025014A2 (fr) 2003-03-27
US20140004136A1 (en) 2014-01-02
WO2003025014A3 (fr) 2004-02-19
EP1427755A2 (fr) 2004-06-16
CA2460704A1 (fr) 2003-03-27
AU2002362383B2 (en) 2008-10-09

Similar Documents

Publication Publication Date Title
AT500379B1 (de) Tau-proteine
DE69431060D1 (de) Klonierte glutaminsäure-decarboxylase
MA30962B1 (fr) Anticorps antifacteurs d'humanisés et leurs utilisations.
ATE384077T1 (de) Stereoselektive antifibrillogene peptide
EP0711173A4 (en) INSULATED PEPTIDES THAT MAKE 10 COMPLEXES WITH MHC MULEKÜL HLA-C-KLON AND THEIR USE
NO20092860L (no) 2, 6 dioksopiperidin samt farmasoytiske preparater som inneholder disse
DK0643726T3 (da) Peptider af humant p53-protein til anvendelse i sammensætninger, som inducerer humant T-celle-respons, og humane p53-protei
MA29409B1 (fr) Anticorps diriges contre le peptide amyloïde -beta, et methodes pour leurs utilisations
DE60032486D1 (de) Prion protein peptide und deren verwendung
EE200700052A (et) Antikeha he v?i mitme apo-lipoproteiin B fragmendi vastu
ATE399207T1 (de) Lipoxygenaseproteine und für diese kodierende polynukleotide
Takata et al. Possible involvement of small oligomers of amyloid-β peptides in 15-deoxy-δ 12, 14 prostaglandin J2-sensitive microglial activation
FR2829768B1 (fr) Utilisation de peptides comportant des modifications de type post-traductionnel dans le cadre du traitement de pathologies auto-immunes
JP4705567B2 (ja) 免疫調整活性、抗炎症活性、および抗ウイルス活性を有するペプチドおよびペプチド模倣物
DK0687180T3 (da) Fremgangsmåde til påvisning og behandling af individer, som har unormale celler, som udtrykker HLC-A2/tyrosinasepeptid-anti
FR2724320B1 (fr) Nouvel implant pour le traitement des maladies acquises
DE60043104D1 (de) Mit rheumatischer arthritis assoziierte spleissvariante von cd44
ATE289612T1 (de) Diagnostische verwendungen von gegen acetylcholinesterase oder deren c-terminale peptide gerichteten antikörpern
ATE75754T1 (de) Monoklonale antikoerper gegen atriale, natriurethische peptide.
RU95120299A (ru) Набор "па-тест" для диагностики неврологических заболеваний
BR0308095A (pt) Teste para anticorpos anti-ingap
ES2145061T3 (es) Diagnostico y terapia a base de peptidos para el tratamiento de las espondiloartropatias.
Truscott Degradation of Long‐Lived Proteins as a Cause of Autoimmune Diseases
CN114981661A (zh) 用于诊断与嗜中性粒细胞胞外陷阱相关的纤溶功能不全的方法
BR0309019A (pt) Associação de um antitrombótico e de aspirina, e sua utilização para o tratamento das doenças aterotrombóticas

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 16

PLFP Fee payment

Year of fee payment: 17

PLFP Fee payment

Year of fee payment: 18

PLFP Fee payment

Year of fee payment: 19

PLFP Fee payment

Year of fee payment: 20